Numerous people within pharma lament the existing challenges and look back to a gilded era when blockbusters provided rivers of money flow and supported growth primarily based activities – both R&D and promoting. And but, could this present biotech’s greatest chance as an market?

yoursite.com are all as well familiar with how the economics for major pharma have changed in the final couple of years. Aspects incorporate:

patent expiries (existing and imminent)
declining R&D productivity (as measured by much more dollars for fewer approved products)
healthcare payor pressures as governments search for price range cuts in all areas
paucity of future blockbusters in the pipeline
Biotech has usually been suggested as a saviour with the suggestion that a focused analysis style primarily based on deep insights, rather than wide pools of area knowledge and serendipity, would lead to higher R&D productivity. Soon after more than 30 years of attempting, there doesn’t seem to be any conclusive proof that biotech’s investigation approach has had any much more achievement. But, there is still result in for hope, even though for reasons driven by necessity and economics rather than just science.

Biotechs by their nature start out (and often remain) as modest, nimble providers getting to discover a niche inside a substantially greater ecosystem. As with any smaller organism or company, you survive by becoming really great at a focused area or creating niche knowledge. You just do not have the resources to compete with the major players.

Thinking about target markets, regardless of the best-line attractiveness of blockbusters, biotechs usually target niche indications. When these might be smaller and initially only have sales possible in the hundreds of millions of dollars, that can nonetheless make a significant distinction to a tiny firm. The equation for big pharma is much tougher as they have to have new drugs, for growth or to replace patent expiries, to create greater sales to move the efficiency needle. And yet some drugs which commence of in niche (or even orphan) indications, achieve approval and then widen their industry chance via label extension. Some examples incorporate:

Amgen’s erythropoietin stimulating agent, or ESA, franchise, including Epogen (also know as epoetin) and Aranesp. Epogen was initially authorized in 1989 for anaemia in patients with end stage renal illness, selling $one hundred million in 1989. By 1997, the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) had been thinking about an “proof primarily based clinical practice guideline on the use of epoetin in cancer patients”. Considering that Amgen had licensed non-chronic kidney applications to J&J (developed as Procrit), they further capitalised on expanding use of Epogen in cancer anaemia by building Aranesp, authorized in 2001. By 2010, Epogen and Aranesp had combined sales of around $5 billion, from Amgen 2010 10K SEC filing.

Other orphan drugs can end up getting priced so richly that even these can lead to blockbuster status eventually. An example is Genzyme’s Gauchers illness franchise and Cerezyme which has more than $1 billion in sales (and in no small element driving Sanofi-Aventis acquisition of Genzyme this year for $20 billion).

Yet another instance of growth by way of label-extension use contains Cephalon’s drug for sleep disorders, Modafinil or Provigil (trade name). This was originally authorized by the FDA in 1998 for enhanced wakefulness in patients with narcolepsy. In 2004, this label was expanded for approval to “boost wakefulness in patients with excessive sleepiness (ES) linked with obstructive sleep apnea/ hypopnea syndrome (OSAHS) and shift perform disorders (SWD)”. Provigil sales had been $25 million 1999, the year of launch, and had grown to $1.12 billion by 2010. Nuvigil, a single-isomer formulation of Provigil, was authorized in 2009, and developed to extend the sleep disorder franchise. This had 2010 sales of $186 million. Provigil and Nuvigil comprised around 46% of total Cephalon sales by 2010 (data from Cephalon 2010 SEC 10-K filings). Provigil’s development by way of the company’s earlier history provided a significant cashflow bedrock to enable further pipeline development. Interestingly, Teva is acquiring Cephalon for $six.8 billion. When a single considers contribution to sales, and how its helped pipeline development, Provigil has played a big portion in supporting this transaction.
Other components supporting a niche focus include things like the escalating hurdle with phase II failures. Reporting in Nature Reviews Drug Discovery, the Centre for Medicines Research found that “Phase II success prices for new development projects have fallen from 28% (2006-2007) to 18% (2008-2009)”. In his blog reviewing what’s behind the phase II failures, Derek Lowe (In the Pipeline) notes that 4 therapeutic regions accounted for more than 70% of the failures – cardiovascular, CNS, metabolic illnesses (diabetes) and oncology. He recognises oncology and CNS as traditional higher danger regions and diabetes is a difficult effectively-served market place with higher current standard of care (generating the efficacy barrier larger). However in cardiovascular, he suggests staying away from the large, apparent plays:

…that is exciting, since that area has traditionally had one of the improved trial achievement rates. Possibly that one particular is also suffering from the common of care getting fairly superior (and normally generic, or quickly to be). So the higher-achievement-price mechanisms of the old days are effectively covered, leaving you to attempt your luck in the riskier tips, even though still attempting to beat some quite good (and quite inexpensive) drugs…